What it's for (Indications)
- Tenoxicam, a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, is indicated for the symptomatic treatment of various inflammatory and degenerative rheumatic diseases, as well as acute musculoskeletal disorders.
- Its primary applications include the management of pain, inflammation, and stiffness associated with conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
- Furthermore, tenoxicam is prescribed for acute periarticular disorders like tendinitis, bursitis, and sprains, offering relief from associated pain and swelling.
- It may also be utilized in the short-term treatment of acute gouty arthritis and for the management of post-operative pain or primary dysmenorrhea, when its anti-inflammatory and analgesic properties are clinically warranted.
- The therapeutic goal is to alleviate symptoms, thereby improving patient mobility and quality of life, rather than altering the underlying disease progression.
- Prescribing decisions are made based on the severity of symptoms and individual patient response, adhering to the principle of using the lowest effective dose for the shortest duration necessary.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The standard adult oral dosage for tenoxicam is typically 20 mg administered once daily. This can be taken as a single tablet or, in certain acute situations, an initial parenteral dose (intramuscular or intravenous) of 20 mg once daily may be given for the first one to two days, followed by the oral maintenance dose. For acute musculoskeletal disorders and acute gout, the dosage may be initiated at 40 mg once daily for the first two days, then reduced to 20 mg once daily for up to one week. It is crucial to administer tenoxicam with or immediately after food to minimize potential gastrointestinal irritation. Dosage adjustments may be necessary in elderly patients, where the lowest effective dose should be considered due to potential age-related physiological changes that could affect drug clearance. Patients with mild to moderate renal or hepatic impairment should also be monitored closely, and dose reductions may be warranted. Tenoxicam should always be used at the lowest effective dose for the shortest possible duration to mitigate the risk of adverse effects, in line with current pharmacological guidelines for NSAID use. Patients should be advised against exceeding the recommended daily dose. |
Safety & Warnings
Common Side Effects
- Like all NSAIDs, tenoxicam carries a risk of various side effects, ranging from mild to severe, primarily affecting the gastrointestinal (GI), cardiovascular, and renal systems.
- Common GI adverse effects include dyspepsia, nausea, vomiting, abdominal pain, diarrhea, constipation, and flatulence.
- More serious GI complications, which can be life-threatening, include peptic ulceration, perforation, and bleeding, particularly in elderly patients or those with a history of GI disease.
- Cardiovascular risks encompass hypertension, edema, and an increased risk of serious thrombotic events such as myocardial infarction and stroke.
- Renal adverse effects may manifest as impaired renal function, acute renal failure, interstitial nephritis, and papillary necrosis, especially in patients with pre-existing renal impairment, heart failure, or dehydration.
- Hepatic effects, though rare, can include elevated liver enzymes and severe liver injury.
- Central nervous system side effects might involve headache, dizziness, somnolence, and vertigo.
- Dermatologic reactions can range from rash and pruritus to severe cutaneous adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.
- Hematologic effects, such as prolonged bleeding time due to platelet aggregation inhibition, and less commonly, anemia or thrombocytopenia, are also possible.
- Patients should be educated on potential side effects and advised to seek immediate medical attention for any severe or persistent symptoms.
Serious Warnings
- Black Box Warning: Tenoxicam, similar to other non-steroidal anti-inflammatory drugs (NSAIDs), carries significant risks that necessitate prominent warnings regarding cardiovascular and gastrointestinal adverse events. **Cardiovascular Thrombotic Events:** NSAIDs, including tenoxicam, have been shown to increase the risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may manifest early in the course of treatment and may increase with prolonged use. Patients with pre-existing cardiovascular disease or those with significant risk factors for cardiovascular disease may be at an elevated risk. Tenoxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery, as NSAIDs increase the risk of myocardial infarction and stroke following such procedures. Healthcare professionals must carefully assess the balance of potential benefits against these substantial risks before initiating tenoxicam, particularly in patients with any cardiovascular comorbidities or predispositions. **Gastrointestinal Risk:** Tenoxicam, like all NSAIDs, is associated with an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can lead to fatal outcomes. These severe events can occur at any point during therapy, often without preceding warning symptoms. Elderly patients, individuals with a prior history of peptic ulcer disease, and/or a history of GI bleeding are at a considerably higher risk for these serious GI complications. Concomitant use of aspirin, oral corticosteroids, or anticoagulants further amplifies this risk. Patients should be thoroughly informed about the signs and symptoms indicative of serious GI adverse events (e.g., unusual stomach pain, black or tarry stools, vomit that looks like coffee grounds), and the medication should be discontinued immediately if any such event is suspected.
- Tenoxicam, like other NSAIDs, carries significant warnings due to its potential for serious adverse events.
- A boxed warning highlights the increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
- This risk may occur early in treatment and may increase with duration of use.
- Tenoxicam is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
- Additionally, a boxed warning emphasizes the increased risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
- These events can occur at any time during use, without warning symptoms, and in patients with or without a history of serious GI events.
- Elderly patients and those with a history of peptic ulcer disease and/or GI bleeding are at greater risk.
- Contraindications include hypersensitivity to tenoxicam, aspirin, or other NSAIDs, active peptic ulcer or gastrointestinal bleeding, severe renal or hepatic impairment, severe heart failure, and the third trimester of pregnancy due to premature closure of the ductus arteriosus.
- Caution is advised in patients with a history of hypertension, fluid retention, cardiovascular disease, asthma, coagulation disorders, and in those concurrently using anticoagulants, corticosteroids, diuretics, or ACE inhibitors due to increased risk of adverse effects or reduced efficacy of co-administered drugs.
- Regular monitoring of renal function, blood pressure, and complete blood counts is recommended during prolonged therapy.
How it Works (Mechanism of Action)
Tenoxicam exerts its therapeutic effects primarily through the inhibition of cyclooxygenase (COX) enzymes, which are pivotal in the synthesis of prostaglandins from arachidonic acid. Specifically, tenoxicam is a non-selective inhibitor of both COX-1 and COX-2 isoenzymes. The COX-1 enzyme is constitutively expressed and plays a crucial role in maintaining gastric mucosal integrity, regulating renal blood flow, and facilitating platelet aggregation. Conversely, the COX-2 enzyme is primarily inducible at sites of inflammation and is responsible for the production of prostaglandins that mediate pain, fever, and the inflammatory response. By inhibiting both COX-1 and COX-2, tenoxicam reduces the formation of various prostaglandins and thromboxanes. This reduction in pro-inflammatory mediators leads to its potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) properties. The anti-inflammatory effect is mediated by decreasing prostaglandin-induced vasodilation and edema, while the analgesic effect stems from reduced prostaglandin sensitization of nociceptive nerve endings. Its antipyretic action is due to the inhibition of prostaglandin synthesis in the hypothalamus, which helps reset the body's thermoregulatory set point during fever. The non-selective inhibition, particularly of COX-1, contributes to the potential gastrointestinal and antiplatelet side effects commonly associated with this class of drugs.